Alessandra Tedeschi, MD

ASST Grande Ospedale Metropolitano Niguarda, Italy

Poster(s):

• 1402 - Cytogenetic instability and therapeutic pressure in Fixed vs Continuous regimens for Chronic Lymphocytic Leukemia after first line treatment: Preliminary Data from an Italian Multicenter Experience

• 1414 - Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia /small lymphocytic lymphoma in the phase 2 CAPTIVATE study

• 1420 - Combination of Zanubrutinib + Venetoclax for Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results in SEQUOIA Arm D

• 1421 - Safety and Efficacy of Zanubrutinib in a Subgroup of Older Patients (≥75 Years) With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma From the SEQUOIA Study

• 1424 - Safety Analysis of Fixed-Duration Acalabrutinib-Venetoclax Combinations vs Chemoimmunotherapy: A Post Hoc Analysis From the Phase 3 AMPLIFY Trial

• 1514 - Updated Results From the Phase 1 Study of Sonrotoclax (BGB-11417), a Novel B-Cell Lymphoma 2 Inhibitor, in Combination With Zanubrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Demonstrate Deep and Durable Responses

• 1708 - Chronic Obstructive Pulmonary Disease and Previous Pneumonia have an impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with Acalabrutinib and Zanubrutinib: a Multicentre SEIFEM Study.

• 1709 - Impact of Dose Intensity of Ibrutinib on Clinical Outcomes of CLL Patients: Analysis of the EVIdeNCE Study